Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alisertib + sapanisertib
- Development stage
- Phase 1
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alisertib + sapanisertib is an investigational combination therapy consisting of two small molecule inhibitors targeting distinct oncogenic pathways. Alisertib is an Aurora A kinase inhibitor that disrupts mitotic spindle formation and cell division, while sapanisertib (MLN0128) is a dual mTORC1/2 inhibitor that blocks the mammalian target of rapamycin pathway involved in cell growth and survival. The combination has been evaluated in phase 1b/2 clinical trials for patients with advanced or refractory solid tumors, including pancreatic adenocarcinoma. Preclinical studies suggested potential synergy by overcoming resistance mechanisms associated with monotherapy. Clinical results indicate modest activity overall but notable responses in select patients; toxicity was consistent with known profiles of each agent[1][5].
- Other names
- sapanisertib + alisertibTAK-228 + MLN8237MLN0128 + MLN8237INK128 + MLN8237
02
Targets
AURKA (Aurora kinase A)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on alisertib + sapanisertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alisertib + sapanisertib.